Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Oncological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAO-A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAO-A Recombinant Protein (Catalytic Domain) — High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. Theoretical MW documented. | View MAOA Products |
| Gene Delivery | MAO-A Lentivirus Particles — Full-length ORF with mitochondrial targeting sequence for stable cell lines. HEK293 Expressed. | View MAOA Products |
| Benchmark Ab | Anti-MAO-A Recombinant Antibody (Research Grade) — Sequence verified clone for WB/IHC/IF validation. | View MAOA Products |
| Validator | MAO-A siRNA Set — For knockdown verification and specificity controls. | View MAOA Products |
| Isoform Control | MAO-B Recombinant Protein — For selectivity screening (critical for safety profiling). | View MAOB Products |
| Pathway Partner (5-HT2A) | HTR2A (5-HT2A Receptor) — Downstream serotonin signaling analysis. | View HTR2A Products |
| Pathway Partner (SERT) | SLC6A4 (Serotonin Transporter) — Synergistic serotonin reuptake modulation. | View SLC6A4 Products |
| Pathway Partner (Biosynthesis) | TPH2 (Tryptophan Hydroxylase 2) — Key enzyme in serotonin biosynthesis. | View TPH2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (MAO-A vs MAO-B) | Human MAO-A and MAO-B ortholog proteins available; >95% purity; matched specifications for direct comparison assays. |
| Mitochondrial Localization Preservation | Lentivirus particles encoding native mitochondrial targeting sequences; stable cell lines retain enzymatic conformation. |
| Mechanism Discrimination (Reversible vs Irreversible) | High-purity active enzyme preparations suitable for kinetic binding and displacement assays; support dilution-recovery experiments. |
| False Positives in Screening | Validated siRNA included for target specificity verification; rescue experiments. |
| Enzyme Stability in High-Throughput Screening | Endotoxin Controlled, Sequence Verified proteins ensuring consistent structural integrity. |
| Lack of Reliable Controls | Recombinant positive control antibodies and benchmark sequences included. |
| Structural/Binding Studies | High-purity catalytic domain suitable for SPR and crystallography. |
Live MAO-A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for MAO-A inhibitors is undergoing a paradigm shift from traditional irreversible monoamine oxidase inhibitors (MAOIs) toward reversible inhibitors of monoamine oxidase A (RIMAs) with improved safety profiles. Concurrently, emerging oncology research positions MAO-A as a critical driver in prostate cancer progression, metastasis, and immune evasion in the tumor microenvironment. The next wave of R&D targets isoform-selective ligands with improved safety margins, peripheral-acting analogs to minimize central serotonin syndrome risk, and novel modalities such as targeted protein degradation (PROTACs) for neurodegenerative diseases. As precision psychiatry advances, subtype-selective modulation and tissue-specific delivery mechanisms are becoming key focus areas. Combination strategies with immune checkpoint inhibitors are also gaining traction in immuno-oncology.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (RIMA) | Roche, Lundbeck, Validus Pharmaceuticals | Major Depression, Social Anxiety | Isoform Selectivity Panel (Need both MAO-A and MAO-B proteins) |
| Irreversible Inhibitor | Generic (Phenelzine, Tranylcypromine) | Atypical Depression, Parkinson's | Covalent Binding Kinetics (Need high-concentration stable protein) |
| Oncology Research (Repurposed/Reversible Analogs) | Johns Hopkins University, Cornell, UCLA | Prostate Cancer, Glioma, TME | Cell-based Mitochondrial Assays (Need Lentivirus stable lines) |
| Chemical Probes / Neuroimaging | Scripps Research Institute | PET imaging, Binding validation | High-affinity Binding Validation (Need purified antigen) |
| PROTACs | Emerging Startups | Neurodegeneration | Degradation Assays (Need Validated Antibodies / siRNA) |
| Combination Therapy (Immuno-oncology) | Immuno-oncology biotechs | Neurology, Oncology | Pathway panel (Need MAO-A + SERT + 5-HT2A reagents) |